Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical GMED has seen impressive momentum in the past year, with its shares soaring 62.1%. It has significantly outperformed the industry’s 7.3% rise and the S&P 500 composite’s 24.8% gain.

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...

BofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, after the company preannounced Q4 revenue that was 3% above the Street ...

Consensus $2.5B. “2024 was an exceptional year of execution and achievement for Globus Medical (GMED). With the NuVasive merger, we believe we created the strongest sales force and best product ...

Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation. Globus Medical expects to report full financial results for 2024 and provide its updated ...